You will only receive an alert if new information was published since you received one.
Facts, news and statistics about antibiotic and antiviral medicine use, resistance and preventive measures.
Public Health Report
Both the number of healthy people colonised with resistant bacteria, and the number of patients who have infections caused by these bacteria have increased.
The Norwegian Institute of Public Health actively participates in over 61 H2020 projects, where the One Health European Joint Programme is one of the largest with 37 partners.
'One Health' is an approach for designing and implementing programmes, policies, legislation and research where multiple sectors communicate and work together to achieve better public health outcomes.
The Norwegian Institute of Public Health has monitored influenza resistance since 2005. Since 2006, samples from all newly diagnosed HIV cases in Norway have also been investigated.
The Norwegian Surveillance System for Antimicrobial Drug Resistance (NORM) is a national health registry that was established in 2000.
We were asked to conduct a systematic review of effect and safety of empiric treatment with antibiotic combination therapy compared with monotherapy for adult patients with septic shock.
The annual report from Resistance against antivirals in Norway (RAVN) with national data about antiviral resistance, focusing on relevant topics related to treatment of viral infections.
The annual report from Resistance against Antivirals in Norway (RAVN) presents national surveillance data on antiviral resistance for a number of viruses.
The annual report from Resistance against Antivirals in Norway (RAVN) presents national surveillance data on antiviral resistance and focuses on topics related to treatment of viral infections.
Systematically review of the evidence on the treatment effects and harms of any antibiotic regimen with an aminoglycoside versus any antibiotic regimen without an aminoglycoside for sepsis in adults.
This is the third report from Resistance against Antivirals in Norway (RAVN). The report includes antiviral medicine use and surveillance data about viral resistance for 2015.
The 2011-2012 report includes general information about the RAVN surveillance system as well as virus resistance in Norway during the period.
This is the second report from Resistance against Antivirals in Norway (RAVN) about the usage of antiviral medicines and surveillance data for viral resistance for the biannual period 2013–2014.
The aim of this study was to explore all Brucella melitensis isolates collected in Norway from 1999 to 2016 in relation to origin of infection and antimicrobial resistance patterns.